Free Trial

Bank Hapoalim BM Grows Stake in Novo Nordisk A/S (NYSE:NVO)

Novo Nordisk A/S logo with Medical background

Bank Hapoalim BM grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 161.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,535 shares of the company's stock after acquiring an additional 13,925 shares during the period. Bank Hapoalim BM's holdings in Novo Nordisk A/S were worth $1,565,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of NVO. Revolve Wealth Partners LLC grew its position in shares of Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock valued at $214,000 after acquiring an additional 200 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Novo Nordisk A/S by 10.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 225,914 shares of the company's stock valued at $19,433,000 after buying an additional 21,331 shares in the last quarter. Victory Capital Management Inc. lifted its stake in shares of Novo Nordisk A/S by 58.5% during the 4th quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock valued at $5,410,000 after buying an additional 23,223 shares in the last quarter. Proficio Capital Partners LLC purchased a new position in shares of Novo Nordisk A/S during the 4th quarter valued at $13,282,000. Finally, HM Payson & Co. lifted its stake in shares of Novo Nordisk A/S by 7.7% during the 4th quarter. HM Payson & Co. now owns 4,441 shares of the company's stock valued at $382,000 after buying an additional 316 shares in the last quarter. Institutional investors own 11.54% of the company's stock.

Analysts Set New Price Targets

NVO has been the topic of a number of analyst reports. Dbs Bank cut shares of Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Hsbc Global Res upgraded shares of Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Wall Street Zen upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Saturday, June 14th. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. Finally, BNP Paribas began coverage on shares of Novo Nordisk A/S in a research note on Tuesday, April 15th. They set an "underperform" rating on the stock. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $112.00.

Read Our Latest Stock Analysis on Novo Nordisk A/S

Novo Nordisk A/S Price Performance

NVO stock traded up $0.31 during mid-day trading on Tuesday, hitting $69.63. The company had a trading volume of 9,838,730 shares, compared to its average volume of 7,271,480. The company has a quick ratio of 0.56, a current ratio of 0.74 and a debt-to-equity ratio of 0.70. Novo Nordisk A/S has a 12-month low of $57.00 and a 12-month high of $143.69. The company has a 50-day moving average price of $70.10 and a 200 day moving average price of $75.41. The company has a market capitalization of $310.90 billion, a price-to-earnings ratio of 20.60, a P/E/G ratio of 1.35 and a beta of 0.64.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting the consensus estimate of $0.92. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. The firm had revenue of $11.87 billion for the quarter. On average, research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

About Novo Nordisk A/S

(Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

See Also

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Should You Invest $1,000 in Novo Nordisk A/S Right Now?

Before you consider Novo Nordisk A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.

While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines